Abstract
Aberrantly high mTORC1 signaling is a known driver of many cancers and human disorders, yet pharmacological inhibition of mTORC1 rarely confers durable clinical responses. To explore alternative therapeutic strategies, herein we conducted a proteomics survey to identify cell surface proteins upregulated by mTORC1. A comparison of the surfaceome from Tsc1-/- versus Tsc1+/+ mouse embryonic fibroblasts revealed 59 proteins predicted to be significantly overexpressed in Tsc1-/- cells. Further validation of the data in multiple mouse and human cell lines showed that mTORC1 signaling most dramatically induced the expression of the proteases neprilysin (NEP/CD10) and aminopeptidase N (APN/CD13). Functional studies showed that constitutive mTORC1 signaling sensitized cells to genetic ablation of NEP and APN, as well as the biochemical inhibition of APN. In summary, these data show that mTORC1 signaling plays a significant role in the constitution of the surfaceome, which in turn may present novel therapeutic strategies.
Footnotes
Author contributions: J. Wei and M.J.E. designed research; J. Wei, K.L., and C.T. performed research; J. Wei, K.L., D.R., and M.J.E. analyzed data; J. Wei, K.L., and M.J.E. wrote the paper; D.R. and J. Wells contributed new reagents/analytic tools.
- Received September 18, 2019.
- Revision received November 4, 2019.
- Accepted December 2, 2019.
- Published under license by The American Society for Biochemistry and Molecular Biology, Inc.
